Pioneering discovery and therapeutics at the brain-vascular-immune interface
A new paper in Cell, “Pioneering discovery and therapeutics at the brain-vascular-immune interface,” describes COVID-19 as a neurological disease alongside multiple sclerosis, Alzheimer’s, stroke and traumatic brain injury.
“COVID-19 can accelerate progression of dementia and induce BBB disruption and inflammatory blood clots causally linked with neuroinflammation and neuronal loss.8 In neurodevelopmental disorders, prematurity and perinatal hypoxia that trigger brain hemorrhage and BBB disruption are risk factors for cerebral palsy, intellectual disability, and autism. Collectively, these risk factors highlight the interconnected vascular and immune triggers of neurological diseases.”
Inflammation may link COVID-19 severity to the onset of neurological symptoms
“neuroinflammation is independent of disease severity and may be one of the main causes of neurological disorders associated with COVID-19. She points out that even patients with milder cases showed significant changes in the CSF, suggesting that the body's inflammatory response may affect the brain in ways not yet fully understood.”
neuroinflammation is independent of disease severity and may be one of the main causes of neurological disorders associated with COVID-19. She points out that even patients with milder cases showed significant changes in the CSF, suggesting that the body's inflammatory response may affect the brain in ways not yet fully understood.